{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:31:37Z","timestamp":1761514297377,"version":"3.37.3"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81600131","81770126","81770161"],"award-info":[{"award-number":["81600131","81770126","81770161"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fujian Natural Science Foundation of China","award":["2017J01354","2017J01360"],"award-info":[{"award-number":["2017J01354","2017J01360"]}]},{"name":"Medical Innovation Program of Fujian Province","award":["2016-CXB-7"],"award-info":[{"award-number":["2016-CXB-7"]}]},{"name":"Foundation of Health and Family Planning Commission of in Fujian Province of China","award":["2017-ZQN-83","2017-2-99"],"award-info":[{"award-number":["2017-ZQN-83","2017-2-99"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.yexcr.2018.11.008","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T16:30:28Z","timestamp":1542040228000},"page":"69-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impairment of V\u03b124-J\u03b118+V\u03b211+ natural killer T cells in adult acute lymphoblastic leukemia patients"],"prefix":"10.1016","volume":"374","author":[{"given":"Haijun","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiting","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manman","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanyan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jintao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2018.11.008_bib1","first-page":"1","article-title":"Progress and Innovations in the management of adult acute lymphoblastic leukemia","author":"Jabbour","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.yexcr.2018.11.008_bib2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood Acute lymphoblastic leukemia: progress through collaboration","author":"Pui","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2018.11.008_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.yexcr.2018.11.008_bib4","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia","author":"Maury","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2018.11.008_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/nri3369","article-title":"Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions","author":"Brennan","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.yexcr.2018.11.008_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/nri3328","article-title":"Recognition of CD1d-restricted antigens by natural killer T cells","author":"Rossjohn","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.yexcr.2018.11.008_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01178","article-title":"Natural killer T cells in cancer immunotherapy","author":"Nair","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yexcr.2018.11.008_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/720803","article-title":"Invariant NKT cells as novel targets for immunotherapy in solid tumors","author":"Pilones","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.yexcr.2018.11.008_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/652875","article-title":"Antitumor responses of invariant natural killer T cells","author":"Altman","year":"2015","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.yexcr.2018.11.008_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/82771","article-title":"NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway","author":"Terabe","year":"2000","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.yexcr.2018.11.008_bib11","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20022227","article-title":"Transforming growth factor-\u03b2 production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte\u2013mediated tumor immunosurveillance","author":"Terabe","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.yexcr.2018.11.008_bib12","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0801631105","article-title":"Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population","author":"Coquet","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.yexcr.2018.11.008_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/eji.201242531","article-title":"The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant V\u03b41 TCR","author":"Bai","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.yexcr.2018.11.008_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.it.2016.06.001","article-title":"Differentiation: consider the context","author":"Tian","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.yexcr.2018.11.008_bib15","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1038\/cti.2013.7","article-title":"IL-21 modulates activation of NKT cells in patients with stage IV malignant melanoma","volume":"2","author":"Coquet","year":"2013","journal-title":"Clin. Transl. Immunol. Nat. Publ. Group"},{"key":"10.1016\/j.yexcr.2018.11.008_bib16","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1800429","article-title":"IL-21 selectively protects CD62L + NKT cells and enhances their effector functions for adoptive immunotherapy","author":"Ngai","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexcr.2018.11.008_bib17","first-page":"1555","article-title":"Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma","volume":"126","author":"Bhatt","year":"2015","journal-title":"Blood. Am. Soc. Hematol."},{"key":"10.1016\/j.yexcr.2018.11.008_bib18","first-page":"4723","article-title":"IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. blood","volume":"111","author":"Gowda","year":"2008","journal-title":"Am. Soc. Hematol."},{"key":"10.1016\/j.yexcr.2018.11.008_bib19","article-title":"Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells","author":"Nakagawa","year":"2000","journal-title":"Oncol. Res."},{"key":"10.1016\/j.yexcr.2018.11.008_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00438","article-title":"Immature, semi-mature, and fully mature dendritic cells: toward a DC-cancer cells interface that augments anticancer immunity","author":"Dudek","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yexcr.2018.11.008_bib21","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.95.10.5690","article-title":"Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated V 14 NKT cells","author":"Kawano","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.yexcr.2018.11.008_bib22","article-title":"Antitumor cytotoxicity mediated by ligand-activated human V\u03b124 NKT cells","author":"Kawano","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2018.11.008_bib23","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.178.5.2827","article-title":"IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production","author":"Coquet","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexcr.2018.11.008_bib24","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1001018","article-title":"Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95\/CD178-dependent and is correlated with antigenic potency","author":"Wingender","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexcr.2018.11.008_bib25","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.167.6.3114","article-title":"Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells","author":"Metelitsa","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexcr.2018.11.008_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2010.10.005","article-title":"Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans","author":"Metelitsa","year":"2011","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.yexcr.2018.11.008_bib27","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2008-06-161281","article-title":"Regulation of multiple myeloma survival and progression by CD1d","author":"Spanoudakis","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.yexcr.2018.11.008_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020702","article-title":"CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis","author":"Hix","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.yexcr.2018.11.008_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/j.1476-5381.2012.02108.x","article-title":"Invariant NKT cells increase drug-induced osteosarcoma cell death","author":"Fallarini","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.yexcr.2018.11.008_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01053-10","article-title":"CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV","author":"Miura","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.yexcr.2018.11.008_bib31","doi-asserted-by":"crossref","DOI":"10.1172\/JCI37869","article-title":"V\u03b124-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages","author":"Song","year":"2009","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.yexcr.2018.11.008_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/ni.1942","article-title":"Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A","author":"De Santo","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.yexcr.2018.11.008_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2016.14","article-title":"Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents","author":"Carre\u00f1o","year":"2016","journal-title":"Clin. Transl. Immunol."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482718308553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482718308553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T17:17:33Z","timestamp":1544548653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482718308553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0014482718308553"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2018.11.008","relation":{},"ISSN":["0014-4827"],"issn-type":[{"type":"print","value":"0014-4827"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impairment of V\u03b124-J\u03b118+V\u03b211+ natural killer T cells in adult acute lymphoblastic leukemia patients","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2018.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}